Objective    To determine the effect of Torin2 on cell proliferation and migration in human nonsmall lung cancer A549 cells and investigate its underlying mechanism. Methods    A549 cells were divided into blank control

negative control

and  Torin2 treatment group. CCK8 assay was used to evaluate the cell proliferation. Cell cycle and apoptosis were measured by flow cytometry. Cell migration was examined by Transwell chamber assay. Western blotting was used to detect the expression of relevant proteins. Results    Torin2 significantly inhibited the proliferation of A549 cells in a dose-dependent manner

and the IC50 was 214.96 nmol/L. Flow cytometry results showed that the apoptotic rates were (4.51±1.32)%

(9.56±2.34)%

and (16.40±3.57)%

respe ctively

in the control

and the 200 and 400 nmol/L Torin2 treatment cells

with the treatment groups significantly higher than the control (P0.05). Compared with the control group

the percentage of the cells in G1 phase was increased (P0.05) and that in S phase was decreased significantly (P0.05) in the Torin2 treatment cells. Transwell chamber assay showed that Torin2 treatment decreased the capacity of cell migration. Torin2 decreased the expression levels of Cyclin D1 and phosphorylated Akt473 and 4EBP1

up-regulated the expression of cleaved Caspase 9 in A549 cells. Conclusion     Torin2 inhibits the proliferation of A549 cells

induces the cells arrested in G1/S stage

enhances cell apoptosis and decreases the capacity of cell migration

which might be associated with its suppression on PI3K/Akt/mTOR signal pathway and expression of cell cycle-related protein Cyclin D1.